According to this study, some international teams had worked on this study to discover that how do genomic changes are compared within the cancer cells
On this note, cancer cells are eliminated from it and provide a resistant treatment that could be used for identifying the molecular targets for cancer therapies.
Prostate Cancer Cells Eliminated Comparative Genomics To Provide Resistive Treatment
Researchers had led this study and stated that the study of “subclone elimination analysis which identifies the targets for enhancing the cancer therapies to reveal the L1 retrotransposition is beyond the dynamic source for the cancer heterogeneity.
The resistive treatment can help the patient who suffers from prostate cancer over a period. Many of them usually suffer from this disease after the age of 30 but those with genetic disorders may become the victim of the same at a young age also which is displayed by the study conducted by experts in this field.
In this study, the researchers had introduced many differential sub-clones elimination and resistive analysis (DSER) as this follows the approach which is developed for identifying the molecular targets to improve the therapies within prostate cancer. This has helped them get a better result.
Based on the method performances, the genomic features are having direct comparisons which eradicate and provide resistance to the cancer cells within the post and pre-treatment samples from the patient.
This study utilizes a single patient with metastatic prostate cancer known as ‘A34’ for demonstrating the potential and utility under the DSER method.
According to this study, patient A34 is already studied in the previous findings by the lead researcher Bova and his colleagues last year. This study was firstly demonstrated towards the cancer cells elimination due to the treatments for a solid tumor.
Researcher Bova states that “by performing the DSER within the A34 case had led us all to discover some changes within the DNA to repair the genes named EYA4 and FANCI during his elimination of cancer cells which are sensitized for chemotherapy.
Additionally, he says that for future findings, the drugs are used as targets for the identification of the gene by using the DSER which can ensure the help towards all types of cancer cells within a patient that remains susceptible for the therapy.
According to the researchers, among all the genes one gene is identified by using the EYA4 and DSER which are associated by the adjacent LINE-1 (L1) for a transposon insertion during the evolution of cancer in A34.
These study findings had raised some questions which are surrounded by the therapy role during the L1 activation. The research team had utilized the prostate cancer cell lines for investigating the chemotherapy and androgen-deprivation treatments.
On this note, they are responsible for activating the L1s and contributing to the resistance and elimination of the cancer cell treatment.
Dr. Ketola stated that “we are very much fascinated by finding all the enzalutamide and carboplatin which had turned to L1 transposon machinery within the VCaP and LNCaP but not in 22Rv1 and PC-3.
He adds the statement that “during the L1 activation, VCaP and LNCaP are having further findings inhibited by the antiretroviral drug azidothymidine, as this tells the existed drugs could manipulate the L1 activity within vitro.
Researchers had found pieces of evidence of this study that, L1 activations in tumor samples are derived by the post castration of a patient which suggests the xenograft models, neck cancer cells, and post-chemotherapy head.
This study concludes by suggesting the L1 activation which is responded for the treatments and helps to extend the clinical patient samples, where further studies are required for determining the extent of this research study.